Information Provided By:
Fly News Breaks for October 7, 2016
GWPH
Oct 7, 2016 | 06:22 EDT
Goldman analyst Salveen Richter initiated GW Pharmaceuticals with a Buy saying he expects a solid launch trajectory for lead assets Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome, two severe orphan epilepsies, and is modeling $1.6B in world-wide sales. Richter has a $189 price target on shares based on a blend of discounted cash flow for $161 per shares and M&A value of $349 per share.
News For GWPH From the Last 2 Days
There are no results for your query GWPH